MediWound, the Israeli company and world leader in next-generation enzyme therapies for tissue repair, said it had been selected to receive €16.25 million in funding from the European Innovation Council (EIC) through its Acceleration Program.
The funding will significantly advance the company's development program for patients suffering from diabetic foot ulcers (DFU).
In addition to financial support, selected projects benefit from a range of acceleration services that provide access to global experts, companies, investors and ecosystem players.
“We are honored to have been selected for this prestigious and highly competitive program,” said Ofer Gonen, President and CEO of MediWound.
The program targets an impressive market of up to 34 million diabetic patients (US and Europe) who are at risk of developing the disease in their lifetime. If not properly treated, UPD can lead to serious complications, including amputations, infections and death. Accelerating this program will have a revolutionary impact on future treatment for the millions of patients in this often under-treated population.
MediWound's proposed therapy is a proteolytic enzyme concentrate enriched with bromelain for easy-to-use daily applications. MediWound is due to launch a Phase III study on venous leg ulcers in the second half of 2024, and a Phase II/III study targeting diabetic foot ulcers in the second half of 2025.
Caroline Haïat
Commentaires